Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about 4D MOLECULAR THERAPEUTICS, INC.
09/244D MOLECULAR THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Stat..
AQ
09/244D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data ..
GL
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
PU
08/124D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
08/124D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial ..
AQ
08/124D MOLECULAR THERAPEUTICS : Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Reports Q2 Rev..
MT
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
AQ
08/124D Molecular Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Qua..
CI
08/124D Molecular Therapeutics, Inc. Appoints Nadine Greiner as Chief Human Resources Office..
CI
06/254D MOLECULAR THERAPEUTICS INC. : Termination of a Material Definitive Agreement, Other Eve..
AQ
06/254D Molecular Therapeutics, Inc. Announces Rare Disease Ophthalmology Product Candidate ..
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Growth Index
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Microcap Growth Index
CI
06/254D-110 : Initial clinical safety data at both of the two dose levels in the Phase 1 clinic..
PU
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Index
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Microcap Index
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Value Index
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Microcap Value Index
CI
06/244D MOLECULAR THERAPEUTICS : Says Roche Stops Trial, Cancels Licensing Deal for Eye Drug; S..
MT
06/244D Molecular Shares Hit 52-Week Low After Roche Ends Collaboration Agreement
DJ
06/244D Molecular Therapeutics Gets Termination Notice From Roche
DJ
06/244D MOLECULAR THERAPEUTICS : Announces Rare Disease Ophthalmology Product Candidate Portfol..
AQ
06/214D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to S&P Global BMI Index
CI
06/09Certain Warrants of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement ..
CI
06/09Certain Stock Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agree..
CI
06/0916,833,726 Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agr..
CI
06/08CHOROIDEREMIA PIPELINE : Emerging Therapies and Key pharma players involved by DelveInsigh..
AQ
06/074D MOLECULAR THERAPEUTICS : Appoints Carolyne Zimmermann as Chief Business Officer
AQ
06/074D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer
CI
06/034D MOLECULAR THERAPEUTICS : to Participate in Goldman Sachs 42nd Annual Global Healthcare ..
AQ
05/204D MOLECULAR THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form..
AQ
05/134D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
05/134D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial ..
AQ
05/134D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and P..
GL
05/134D Molecular Therapeutics, Inc. Announces Unaudited Earnings Results for the First Quar..
CI
05/124D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4..
GL
05/124D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4..
CI
05/044D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technolog..
GL
04/304D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Co..
GL
04/274D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Ann..
GL
04/274D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Ann..
CI
04/06Mr. William Burkoth to Not Stand for Re-Election as Director of 4D Molecular Therapeuti..
CI
03/31JOHN MARTIN : John Martin, Who Built Gilead Into HIV, Hepatitis Powerhouse, Dies
DJ
03/264D MOLECULAR THERAPEUTICS : Posts Narrower Net Loss, Higher Revenue in 2020
MT
03/254D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
03/254D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial ..
AQ
03/254D Molecular Therapeutics, Inc. Announces Changes to Its Board
CI
03/254D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 202..
GL
03/254D Molecular Therapeutics Provides Operational Highlights
CI
03/254D Molecular Therapeutics, Inc. Announces Consolidated Earnings Results for the Year En..
CI
03/214D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to S&P TMI Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Value Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2000 Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2500 Growth Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000 Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2500 Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2000 Value Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Small Cap Comp Growth Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2000 Growth Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Small Cap Comp Value Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2500 Value Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2500 Dynamic Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000 Value Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2500 Growth-Dynamic Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2500 Value-Dynamic Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2000 Dynamic Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2000 Growth-Dynamic Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 2000 Value-Dynamic Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Growth Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Small Cap Completeness Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000 Growth Index
CI
03/184D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Index
CI
03/094D MOLECULAR THERAPEUTICS : Doses First Patient in Phase 1/2 Trial of 4D-310 to Treat Fabr..
MT
03/094D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
GL
03/094D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
CI
1  2Next